Alx oncology strengthens immuno-oncology pipeline with acquisition of scalmibio

South san francisco, calif., oct. 07, 2021 (globe newswire) -- alx oncology holdings inc. (“alx oncology”) (nasdaq: alxo), a clinical-stage immuno-oncology company, and scalmibio, inc. (“scalmibio”) announced today that alx oncology has acquired scalmibio.

ALXO Ratings Summary

ALXO Quant Ranking